Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.
Preoperative vitamin D deficiency is associated with postoperative symptomatic hypocalcemia in patients with thyroid cancer undergoing total thyroidectomy plus central compartment neck dissection.
In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with Î²-aminopropionitrile fumarate.
The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.
Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.
Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer
Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.
Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies
The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.